Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
Public ClinicalTrials.gov record NCT02600819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis
Study identification
- NCT ID
- NCT02600819
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Gilead Sciences
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- E/C/F/TAF Drug
- B/F/TAF Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2015
- Primary completion
- Sep 28, 2017
- Completion
- Oct 14, 2019
- Last update posted
- Nov 4, 2020
2015 – 2019
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Peter J Ruane MD Inc | Los Angeles | California | — | — |
| University of California Davis | Sacramento | California | — | — |
| Midway Immunology & Research Center, LLC | Ft. Pierce | Florida | — | — |
| Infectious Disease Consultants, M.D., P.A. d/b/a Orlando Immunology Center | Orlando | Florida | — | — |
| Triple O Research Institute PA | West Palm Beach | Florida | — | — |
| Medical College of Georgia | Augusta | Georgia | — | — |
| Infectious Disease Specialists of Atlanta | Decatur | Georgia | — | — |
| Mercer University School of Medicine | Macon | Georgia | — | — |
| The Research Institute | Springfield | Massachusetts | — | — |
| Henry Ford Health System | Detroit | Michigan | — | — |
| Prime Health Care Services - St Michael's LLC d/b/a Saint Michael's Medical Center | Newark | New Jersey | — | — |
| University of North Carolina at Chapel Hill / UNC School of Medicine | Chapel Hill | North Carolina | — | — |
| Duke University | Durham | North Carolina | — | — |
| Wake Forest University Baptist Medical Center | Winston-Salem | North Carolina | — | — |
| University of Cincinnati Med Center | Cincinnati | Ohio | — | — |
| MetroHealth Medical Center IRB | Cleveland | Ohio | — | — |
| North Texas Infectious Diseases Consultants | Dallas | Texas | — | — |
| Trinity Health and Wellness Center | Fort Worth | Texas | — | — |
| Gordon E. Crofoot MD PA | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02600819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02600819 live on ClinicalTrials.gov.